Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption

April Armstrong; Brian Keegan; George  Han; Abby Jacobson

doi:10.25251/skin.5.supp.50

April Armstrong

Keck School of Medicine at University of Southern California, Los Angeles, CA, USA

Brian Keegan

Princeton Dermatology Associates, Monroe, N

George Han

Mount Sinai

Abby Jacobson

Ortho Dermatologics

Keywords

brodalumab, retreatment, quality of life, psoriasis

Abstract

N/A

References

1. Aldredge and Higham. J Dermatolog Nurses Assoc. 2018;10:189-197.

2. Siliq [package insert]. Bausch Health US, LLC; 2017.

3. Lebwohl et al. J Drugs Dermatol. 2020;19:384-387.

4. Papp et al. Br J Dermatol. 2016;175:273-286

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.50

How to Cite

Armstrong , A., Keegan, B., Han, G. ., & Jacobson, A. (2021). Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption. SKIN The Journal of Cutaneous Medicine, 5(6), s50. https://doi.org/10.25251/skin.5.supp.50

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Poster Presentations from FC21 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette, Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Graham H Litchman DO, MS, Quinn Thibodeaux, Ryan Rivera-Oyola, John Koo, Rick Fried, Gary Goldenberg, George Han, Sylvia Hsu, Leon Kircik, Melissa Knuckles, Andrea Murina, Jashin Wu, Mark Lebwohl, Should Package Insert Warnings Deter Prescribing in Psoriasis Patients with Depression? , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Danny Zakria, April Armstrong, Brian Berman, James Del Rosso, Mark Lebwohl, Todd Schlesinger, Darrell Rigel, The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
April Armstrong , Bruce Strober , Kenneth Gordon , Joe Zhuo, Brandon Becker, Renata Kisa, John Throup, Jonghyeon Kim, Kim Papp, Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Philip Brown, Leon Kircik, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Bruce Strober, Michael Bukhalo, April Armstrong, David Pariser, Leon Kircik, Sepideh Parhami, Paul Montgomery, Tobin Dickerson, Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Leon Kircik, Philip Brown, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

1 2 3 4 5 6 7 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)